Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib and Olaparib vs Cediranib, Olaparib, or Standard Chemotherapy in Recurrent Platinum-Resistant Ovarian/Fallopian Tube/Peritoneal Cancer
KCT0004526Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cediranib, olaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AstraZeneca. Started Dec 2019; status: recruiting.
02
Drugs
cediranibolaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on KCT0004526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004526.